drug · small molecule

selpercatinib

Marketedupdated 3mo ago

by Eli Lilly and Co🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 2 investigational indications.

indications

investigational

NSCLCBreast CancerColorectal Cancer

targets

Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RETProto-oncogene tyrosine-protein kinase receptor RetKinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET

all catalysts(19)

approval · 19

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

selpercatinib

→

view all 19 catalysts →

Trials studying selpercatinib

phase2A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activationactive not recruitingn=77
phase2Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)recruitingn=13
phase3A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Canceractive not recruitingn=291
phase3A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)active not recruitingn=152
phase2A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumorsactive not recruitingn=36
phase1A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participantscompletedn=16
phase3A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Canceractive not recruitingn=261
phase1A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participantscompletedn=16

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

May 8, 2027

266 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (56)

Apr 10, 2039patentUS 10584124*PED
Apr 10, 2039patentUS 10584124*PED
Apr 10, 2039patentUS 10786489*PED
Apr 10, 2039patentUS 10786489*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Oct 10, 2038compositionUS 10584124
Oct 10, 2038compositionUS 10584124
Oct 10, 2038formulationUS 10786489
Oct 10, 2038formulationUS 10786489
Oct 10, 2038method-of-use (U-3950)US 12138250
Oct 10, 2038method-of-use (U-3949)US 12138250
Oct 10, 2038method-of-use (U-3949)US 12138250
Oct 10, 2038method-of-use (U-3450)US 12138250
Oct 10, 2038method-of-use (U-3450)US 12138250
Oct 10, 2038method-of-use (U-3949)US 12138250
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3950)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10172851
Oct 10, 2037method-of-use (U-3951)US 10172851
Oct 10, 2037method-of-use (U-3951)US 10172851
Oct 10, 2037method-of-use (U-3450)US 10172851
Oct 10, 2037method-of-use (U-3950)US 10172851
Oct 10, 2037method-of-use (U-3951)US 10172851

FDA exclusivities (68)

Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
May 29, 2031ODE*ODE*4.8y
May 29, 2031ODE-484Orphan Drug (7y)4.8y
May 29, 2031ODE-485Orphan Drug (7y)4.8y
May 29, 2031ODE-487Orphan Drug (7y)4.8y
May 29, 2031ODE-484Orphan Drug (7y)4.8y
May 29, 2031ODE-485Orphan Drug (7y)4.8y
May 29, 2031ODE-487Orphan Drug (7y)4.8y
May 29, 2031ODE*ODE*4.8y
May 29, 2031ODE*ODE*4.8y
May 29, 2031ODE*ODE*4.8y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Sep 21, 2029ODE-412Orphan Drug (7y)3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE-412Orphan Drug (7y)3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE-409Orphan Drug (7y)3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE-409Orphan Drug (7y)3.1y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Nov 29, 2027PEDPediatric (6mo bonus)1.3y
Nov 29, 2027PEDPediatric (6mo bonus)1.3y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
May 29, 2027NPPNew Product (3y)287d
May 29, 2027NPPNew Product (3y)287d
May 8, 2027ODE-301Orphan Drug (7y)266d
May 8, 2027ODE-303Orphan Drug (7y)266d
May 8, 2027ODE-302Orphan Drug (7y)266d
May 8, 2027ODE-301Orphan Drug (7y)266d
May 8, 2027ODE*ODE*266d
May 8, 2027ODE-302Orphan Drug (7y)266d
May 8, 2027ODE-303Orphan Drug (7y)266d
May 8, 2027ODE*ODE*266d
May 8, 2027ODE*ODE*266d
May 8, 2027ODE*ODE*266d

News(2)

OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
onclive · 3mo ago
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
onclive · 3mo ago

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

selpercatinib

Marketedupdated 3mo ago

by Eli Lilly and Co🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 4

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 2 investigational indications.

indications

investigational

NSCLCBreast CancerColorectal Cancer

targets

Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RETProto-oncogene tyrosine-protein kinase receptor RetKinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET

all catalysts(19)

approval · 19

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

RETEVMO (SELPERCATINIB) — FDA approval

selpercatinib

→

view all 19 catalysts →

Trials studying selpercatinib

phase2A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activationactive not recruitingn=77
phase2Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)recruitingn=13
phase3A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Canceractive not recruitingn=291
phase3A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)active not recruitingn=152
phase2A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumorsactive not recruitingn=36
phase1A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participantscompletedn=16
phase3A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Canceractive not recruitingn=261
phase1A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participantscompletedn=16

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

May 8, 2027

266 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (56)

Apr 10, 2039patentUS 10584124*PED
Apr 10, 2039patentUS 10584124*PED
Apr 10, 2039patentUS 10786489*PED
Apr 10, 2039patentUS 10786489*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Apr 10, 2039patentUS 12138250*PED
Oct 10, 2038compositionUS 10584124
Oct 10, 2038compositionUS 10584124
Oct 10, 2038formulationUS 10786489
Oct 10, 2038formulationUS 10786489
Oct 10, 2038method-of-use (U-3950)US 12138250
Oct 10, 2038method-of-use (U-3949)US 12138250
Oct 10, 2038method-of-use (U-3949)US 12138250
Oct 10, 2038method-of-use (U-3450)US 12138250
Oct 10, 2038method-of-use (U-3450)US 12138250
Oct 10, 2038method-of-use (U-3949)US 12138250
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10112942*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10137124*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Apr 10, 2038patentUS 10172851*PED
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037compositionUS 10112942
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3950)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10137124
Oct 10, 2037method-of-use (U-3951)US 10172851
Oct 10, 2037method-of-use (U-3951)US 10172851
Oct 10, 2037method-of-use (U-3951)US 10172851
Oct 10, 2037method-of-use (U-3450)US 10172851
Oct 10, 2037method-of-use (U-3950)US 10172851
Oct 10, 2037method-of-use (U-3951)US 10172851

FDA exclusivities (68)

Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
Nov 29, 2031PEDPediatric (6mo bonus)
May 29, 2031ODE*ODE*4.8y
May 29, 2031ODE-484Orphan Drug (7y)4.8y
May 29, 2031ODE-485Orphan Drug (7y)4.8y
May 29, 2031ODE-487Orphan Drug (7y)4.8y
May 29, 2031ODE-484Orphan Drug (7y)4.8y
May 29, 2031ODE-485Orphan Drug (7y)4.8y
May 29, 2031ODE-487Orphan Drug (7y)4.8y
May 29, 2031ODE*ODE*4.8y
May 29, 2031ODE*ODE*4.8y
May 29, 2031ODE*ODE*4.8y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Mar 21, 2030PEDPediatric (6mo bonus)3.6y
Sep 21, 2029ODE-412Orphan Drug (7y)3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE-412Orphan Drug (7y)3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE-409Orphan Drug (7y)3.1y
Sep 21, 2029ODE*ODE*3.1y
Sep 21, 2029ODE-409Orphan Drug (7y)3.1y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Mar 27, 2028PEDPediatric (6mo bonus)1.6y
Nov 29, 2027PEDPediatric (6mo bonus)1.3y
Nov 29, 2027PEDPediatric (6mo bonus)1.3y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Nov 8, 2027PEDPediatric (6mo bonus)1.2y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
Sep 27, 2027M-312Method (3y)1.1y
Sep 27, 2027M-311Method (3y)1.1y
May 29, 2027NPPNew Product (3y)287d
May 29, 2027NPPNew Product (3y)287d
May 8, 2027ODE-301Orphan Drug (7y)266d
May 8, 2027ODE-303Orphan Drug (7y)266d
May 8, 2027ODE-302Orphan Drug (7y)266d
May 8, 2027ODE-301Orphan Drug (7y)266d
May 8, 2027ODE*ODE*266d
May 8, 2027ODE-302Orphan Drug (7y)266d
May 8, 2027ODE-303Orphan Drug (7y)266d
May 8, 2027ODE*ODE*266d
May 8, 2027ODE*ODE*266d
May 8, 2027ODE*ODE*266d

News(2)

OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
onclive · 3mo ago
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
onclive · 3mo ago

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

selpercatinib

🐶 often sniffed alongside

indications

targets

all catalysts(19)

Trials studying selpercatinib

Patent cliff

patents (56)

FDA exclusivities (68)

News(2)

Report a data issue

comments(0)

selpercatinib

🐶 often sniffed alongside

indications

targets

all catalysts(19)

Trials studying selpercatinib

Patent cliff

patents (56)

FDA exclusivities (68)

News(2)

Report a data issue

comments(0)